MedWatch

Orphazyme predicts EU rejection after meeting with CHMP

Biotech company Orphazyme is not holding out much hope for an EU approval of its candidate arimoclomol after its meeting with the expert committee CHMP on Wednesday.

Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750

An indicative vote taken on Wednesday by the CHMP, an expert panel that is part of the European Medicines Agency, did not result in a majority in favor of recommending Orphazyme’s candidate arimoclomol for approval in the region. The CHMP (Committee for Medicinal Products for Human Use) was considering arimoclomol for the indication Niemann Pick type C, a rare metabolic disease also known as NPC.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs